Skip to main content
. 2020 Apr 6;12(4):701–711. doi: 10.4168/aair.2020.12.4.701

Fig. 2. Anaphylaxis symptom scores and rectal temperature. Mice were orally challenged with ovomucoid on day 1 and 14 after discontinuation of OIT and/or Lcr35 treatment. (A) Day 1 after discontinuation of OIT (on OIT) and (B) day 14 after discontinuation of OIT.

Fig. 2

OIT, oral immunotherapy.

*P < 0.05 compared to the control group (vs. No OIT); †P < 0.05 compared to the OIT group (vs. OIT).